Fresenius Kabi Introduces Clofarabine Injection

First-to-market generic for CLOLAR® (clofarabine injection) now available

Fresenius Kabi launches first generic of CLOLAR® (clofarabine injection) for pediatric oncology patients (Photo: Business Wire)

???pagination.previous??? ???pagination.next???

LAKE ZURICH, Ill.--()--Fresenius Kabi announced today the immediate availability in the United States of Clofarabine Injection. Fresenius Kabi Clofarabine Injection is available as a single dose vial containing 20 mg per 20 mL Clofarabine.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

“Fresenius Kabi is pleased to introduce a generic version of this important pediatric cancer medicine,” said John Ducker, president and CEO of Fresenius Kabi USA. “Continuing to develop critical and accessible medicines for all patients is fundamental to the Fresenius Kabi mission of ‘caring for life’.”

Clofarabine Injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.

CLOLAR® is a registered trademark of Genzyme Corporation.

Contacts

Fresenius Kabi
Matt Kuhn
matt.kuhn@fresenius-kabi.com
847-550-5751

Contacts

Fresenius Kabi
Matt Kuhn
matt.kuhn@fresenius-kabi.com
847-550-5751